AC Immune Enters into a Worldwide License and Collaboration Agreement for Alzheimer's Disease Therapeutic anti-Tau Vaccines with Janssen Pharmaceuticals, Inc.
12.January 2015 08:00 CET
- Exclusive worldwide license agreement potentially worth up to USD 509 million (CHF 500 million*)
- Three-year joint program to develop therapeutic vaccines for tauopathies
- Therapeutic vaccines offer the potential to treat Alzheimer's patients earlier in the disease